289 related articles for article (PubMed ID: 30431421)
1. Fosfomycin: mechanisms and the increasing prevalence of resistance.
Aghamali M; Sedighi M; Zahedi Bialvaei A; Mohammadzadeh N; Abbasian S; Ghafouri Z; Kouhsari E
J Med Microbiol; 2019 Jan; 68(1):11-25. PubMed ID: 30431421
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon.
Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS
J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601
[TBL] [Abstract][Full Text] [Related]
4. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
Tariq TM
J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.
Vardakas KZ; Legakis NJ; Triarides N; Falagas ME
Int J Antimicrob Agents; 2016 Apr; 47(4):269-85. PubMed ID: 27013000
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic resistance among bacterial pathogens in Central Africa: a review of the published literature between 1955 and 2008.
Vlieghe E; Phoba MF; Tamfun JJ; Jacobs J
Int J Antimicrob Agents; 2009 Oct; 34(4):295-303. PubMed ID: 19540725
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Morfin-Otero R; Noriega ER; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
[TBL] [Abstract][Full Text] [Related]
9. Fosfomycin.
Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections.
Novelli A; Rosi E
J Chemother; 2017 Dec; 29(sup1):10-18. PubMed ID: 29271734
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of antimicrobial resistance and its clinical implications in Ethiopia: a systematic review.
Berhe DF; Beyene GT; Seyoum B; Gebre M; Haile K; Tsegaye M; Boltena MT; Tesema E; Kibret TC; Biru M; Siraj DS; Shirley D; Howe R; Abdissa A
Antimicrob Resist Infect Control; 2021 Dec; 10(1):168. PubMed ID: 34861894
[TBL] [Abstract][Full Text] [Related]
13. Importance of antibiotic resistance and resistance mechanisms. Foreword.
Bonomo RA; Rossolini GM
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):549-50. PubMed ID: 18847392
[No Abstract] [Full Text] [Related]
14. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.
Marchese A; Gualco L; Debbia EA; Schito GC; Schito AM
Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():53-9. PubMed ID: 14527772
[TBL] [Abstract][Full Text] [Related]
15. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study.
Piroth L; Pechinot A; Minello A; Jaulhac B; Patry I; Hadou T; Hansmann Y; Rabaud C; Chavanet P; Neuwirth C
Scand J Infect Dis; 2009; 41(11-12):847-51. PubMed ID: 19922067
[TBL] [Abstract][Full Text] [Related]
16. Shifting trends in bacterial keratitis in Toronto: an 11-year review.
Lichtinger A; Yeung SN; Kim P; Amiran MD; Iovieno A; Elbaz U; Ku JY; Wolff R; Rootman DS; Slomovic AR
Ophthalmology; 2012 Sep; 119(9):1785-90. PubMed ID: 22627118
[TBL] [Abstract][Full Text] [Related]
17. The state of ESKAPE in Malaysia.
McNeil HC; Lean SS; Lim V; Clarke SC
Int J Antimicrob Agents; 2016 Nov; 48(5):578-579. PubMed ID: 27742200
[No Abstract] [Full Text] [Related]
18. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
Schito GC; Naber KG; Botto H; Palou J; Mazzei T; Gualco L; Marchese A
Int J Antimicrob Agents; 2009 Nov; 34(5):407-13. PubMed ID: 19505803
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotic sensitivity of microorganisms, isolated from patients with opportunistic infections].
Tymchyk OV; Shapiro AV; Vasylenko OH
Mikrobiol Z; 2005; 67(5):64-8. PubMed ID: 16396113
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial resistance among isolates cultured from patients hospitalized with lower respiratory tract infection in Europe.
Fluit AC; Verhoef J; Schmitz FJ;
Int J Infect Dis; 2002 Jun; 6(2):144-6. PubMed ID: 12146499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
